Galectin-3:KRAS 成瘾性癌症的可成药脆弱点
该研究在临床前模型中揭示半乳糖凝集素-3(galectin-3)是 KRAS 依赖性的关键环节:其与整合素 αvβ3 结合支持 KRAS 突变细胞的巨胞饮与氧化还原平衡,阻断该结合可抑制巨胞饮并升高活性氧,从而清除表达 αvβ3 的 KRAS 突变肺癌和胰腺癌患者来源异种移植瘤及小鼠自发肿瘤。
要点
- Galectin-3 通过结合整合素 αvβ3 支持 KRAS 依赖细胞的巨胞饮和氧化还原平衡。
- 阻断 αvβ3/galectin-3 结合可抑制巨胞饮并升高活性氧,清除 KRAS 突变肺癌和胰腺癌模型。
- 整合素 αvβ3 被提出作为识别对 galectin-3 抑制敏感的 KRAS 成瘾性肿瘤的生物标志物。
核心结论
- Galectin-3 是 KRAS 成瘾性肺癌和胰腺癌的可成药靶点,整合素 αvβ3 可用于识别对该抑制敏感的肿瘤。
研究设计与样本
- 临床前研究,使用 KRAS 突变肺癌和胰腺癌患者来源异种移植瘤及小鼠自发肿瘤模型。
主要发现
- Galectin-3 直接结合细胞表面受体整合素 αvβ3,通过支持 KRAS 在非锚定依赖细胞中的多种功能(包括形成巨胞饮体促进营养摄取和维持氧化还原平衡)导致 KRAS 成瘾。
- 用临床活性药物破坏 αvβ3/galectin-3 结合可阻止其与突变 KRAS 关联,抑制巨胞饮并升高活性氧,从而清除表达 αvβ3 的 KRAS 突变肺癌和胰腺癌患者来源异种移植瘤及小鼠自发肿瘤。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Identifying the molecular basis for cancer cell dependence on oncogenes such as KRAS can provide new opportunities to target these addictions. Here, we identify a novel role for the carbohydrate-binding protein galectin-3 as a lynchpin for KRAS dependence. By directly binding to the cell surface receptor integrin αvβ3, galectin-3 gives rise to KRAS addiction by enabling multiple functions of KRAS in anchorage-independent cells, including formation of macropinosomes that facilitate nutrient uptake and ability to maintain redox balance. Disrupting αvβ3/galectin-3 binding with a clinically active drug prevents their association with mutant KRAS, thereby suppressing macropinocytosis while increasing reactive oxygen species to eradicate αvβ3-expressing KRAS-mutant lung and pancreatic cancer patient-derived xenografts and spontaneous tumors in mice. Our work reveals galectin-3 as a druggable target for KRAS-addicted lung and pancreas cancers, and indicates integrin αvβ3 as a biomarker to identify susceptible tumors.Significance: There is a significant unmet need for therapies targeting KRAS-mutant cancers. Here, we identify integrin αvβ3 as a biomarker to identify mutant KRAS-addicted tumors that are highly sensitive to inhibition of galectin-3, a glycoprotein that binds to integrin αvβ3 to promote KRAS-mediated activation of AKT. Cancer Discov; 7(12); 1464-79. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1355.
引用
- Seguin L, Camargo MF, Wettersten HI, et al. Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discov. 2017. PMID: 28893801. doi:10.1158/2159-8290.CD-17-0539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。